Case Form
Find Out if You Potentially Qualify for a Financial Reward by filling out the form.
Viatris issued a press release on February 27, 2025, reporting its fourth quarter and full year 2024 financial results, which missed consensus estimates with respect to key metrics. In addition, Viatris provided lower-than-expected full-year guidance for 2025. Viatris also provided an update on remediation work at a manufacturing facility in India following receipt of a warning letter and import alert from the U.S. Food and Drug Administration, advising that it was “more than halfway through its remediation efforts and expects to be completed in a few months at which time the Company anticipates requesting FDA to conduct a reinspection of the facility.”
Following this news, Viatris’s stock price fell over 15% on the same day.